论文部分内容阅读
目前肺癌已成为我国乃至全世界最常见的恶性肿瘤之一,全世界每年超过90万的人死于肺癌。在确诊的肺癌中, 小细胞肺癌(small cell lung cancer,SCLC)占13％-20％。其侵袭力强,恶性程度高,极易发生早期转移,确诊时绝大多数(约90％)已发生了区域淋巴结和(或)远处转移,丧失了手术治疗的机会,因此放疗及化疗便成为主要的治疗手段。特别是化疗及其他药物治疗实施方便,县级以上医院均可开展。近10年随着对SCLC致病机制认识的加深及分子生物学的发展,新的化疗方案及治疗药物不断涌现,故本文就此作一综述。
At present, lung cancer has become one of the most common malignant tumors in our country and even in the world. More than 900,000 people die from lung cancer each year in the world. In diagnosed lung cancer, small cell lung cancer (SCLC) accounts for 13% -20%. Its invasiveness, high degree of malignancy, prone to early metastasis, the vast majority of confirmed (about 90%) have occurred in regional lymph nodes and (or) distant metastasis, the loss of surgical treatment opportunities, so radiotherapy and chemotherapy will Become the main treatment. In particular, the implementation of chemotherapy and other drug treatment is convenient, hospitals above the county level can be carried out. In the past 10 years, with the deepening of understanding of the pathogenesis of SCLC and the development of molecular biology, new chemotherapy regimens and therapeutic drugs are emerging.